Skip to main content
Top
Published in: BMC Geriatrics 1/2022

Open Access 01-12-2022 | Stroke | Research

Barriers to prescribing oral anticoagulants to inpatients aged 80 years and older with nonvalvular atrial fibrillation: a cross-sectional study

Authors: Xin Xia, Lishuang Wang, Taiping Lin, Jirong Yue, Zhonghua Yang, Chongqing Mi, Zaibo Liao, Yanyu Chen, Ning Ge, Chenkai Wu

Published in: BMC Geriatrics | Issue 1/2022

Login to get access

Abstract

Background

To investigate the temporal trend of the prevalence of underprescription of anticoagulation treatment and explore the factors associated with underprescription of oral anticoagulants (OACs) among inpatients aged ≥ 80 years with nonvalvular atrial fibrillation (NVAF).

Methods

We retrospectively reviewed the medical records of inpatients with a discharge diagnosis of NVAF from a medical database. We used the Pearson chi-square or Fisher’s exact test to compare categorical variables between patients with and without OAC prescriptions during hospitalization. Logistic regression analysis was used to assess the association between risk factors and underprescription of OACs.

Results

A total of 4375 patients aged ≥ 80 years with AF were assessed in the largest academic hospital in China from August 1, 2016, to July 31, 2020, and 3165 NVAF patients were included. The prevalence of underprescription of OACs was 79.1% in 2017, 71.3% in 2018, 64.4% in 2019, and 56.1% in 2020. Of all participants, 2138 (67.6%) were not prescribed OACs; 66.3% and 68.2% of patients with and without prior stroke did not receive OACs, respectively. Age (85–89 vs 80–84, OR = 1.48, 95% CI (1.25–1.74); 90 + vs 80–84, OR = 2.66, 95% CI: 2.09–3.42), clinical department where patients were discharged (Reference = Cardiology, Geriatrics: OR = 2.97, 95% CI: 2.45- 3.61; neurology: OR = 1.25, 95% CI: 0.96, 1.63; others: OR = 4.23, 95% CI: 3.43- 5.24), use of antiplatelets (OR = 1.69, 95% CI: 1.45- 1.97), and history of stroke (OR = 0.83, 95% CI: 0.71- 0.98 adjusted age), and dementia (OR = 2.16, 95% CI: 1.60- 2.96) were significantly associated with not prescribing OACs.

Conclusions

The prevalence of underprescription of OACs has decreased over the past several years. The rate of underprescription of OACs was higher among NVAF patients who were older, prescribed antiplatelets, discharged from nondepartmental cardiology, and suffered from comorbidities. This study found iatrogenic factors affecting the underprescription of OACs in inpatients aged ≥ 80 years, providing clues and a basis for the standardized use of OACs in inpatients.
Literature
1.
go back to reference Sun Y, Zhu J, Ma C, Liu S, Yang Y, Hu D. Stroke Risk Status, Anticoagulation Treatment, and Quality-of-Life in Chinese Patients with Atrial Fibrillation: China Registry of Atrial Fibrillation (CRAF). Cardiovasc Ther. 2019;2019:1–10.CrossRef Sun Y, Zhu J, Ma C, Liu S, Yang Y, Hu D. Stroke Risk Status, Anticoagulation Treatment, and Quality-of-Life in Chinese Patients with Atrial Fibrillation: China Registry of Atrial Fibrillation (CRAF). Cardiovasc Ther. 2019;2019:1–10.CrossRef
2.
go back to reference Guo Y, Tian Y, Wang H, Si Q, Wang Y, Gyh L. Prevalence, incidence, and lifetime risk of atrial fibrillation in China: new insights into the global burden of atrial fibrillation. Chest. 2015;147(1):109–19.CrossRef Guo Y, Tian Y, Wang H, Si Q, Wang Y, Gyh L. Prevalence, incidence, and lifetime risk of atrial fibrillation in China: new insights into the global burden of atrial fibrillation. Chest. 2015;147(1):109–19.CrossRef
3.
go back to reference Sun Y, Hu D. Chinese subgroup analysis of the global anticoagulant registry in the FIELD (GARFIELD) registry in the patients with non-valvular atrial fibrillation. Zhonghua Xin Xue Guan Bing Za Zhi. 2014;42(10):846–50.PubMed Sun Y, Hu D. Chinese subgroup analysis of the global anticoagulant registry in the FIELD (GARFIELD) registry in the patients with non-valvular atrial fibrillation. Zhonghua Xin Xue Guan Bing Za Zhi. 2014;42(10):846–50.PubMed
4.
go back to reference Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J. 2012;33(12):1500–10.CrossRef Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J. 2012;33(12):1500–10.CrossRef
5.
go back to reference Forslund T, Wettermark B, Wandell P, von Euler M, Hasselstrom J, Hjemdahl P. Risks for stroke and bleeding with warfarin or aspirin treatment in patients with atrial fibrillation at different CHA(2)DS(2)VASc scores: experience from the Stockholm region. Eur J Clin Pharmacol. 2014;70(12):1477–85.CrossRef Forslund T, Wettermark B, Wandell P, von Euler M, Hasselstrom J, Hjemdahl P. Risks for stroke and bleeding with warfarin or aspirin treatment in patients with atrial fibrillation at different CHA(2)DS(2)VASc scores: experience from the Stockholm region. Eur J Clin Pharmacol. 2014;70(12):1477–85.CrossRef
6.
go back to reference Marcucci M, Nobili A, Tettamanti M, et al. Joint use of cardio-embolic and bleeding risk scores in elderly patients with atrial fibrillation. Eur J Intern Med. 2013;24(8):800–6.CrossRef Marcucci M, Nobili A, Tettamanti M, et al. Joint use of cardio-embolic and bleeding risk scores in elderly patients with atrial fibrillation. Eur J Intern Med. 2013;24(8):800–6.CrossRef
7.
go back to reference Mercaldi CJ, Ciarametaro M, Hahn B, et al. Cost efficiency of anticoagulation with warfarin to prevent stroke in medicare beneficiaries with nonvalvular atrial fibrillation. Stroke. 2011;42(1):112–8.CrossRef Mercaldi CJ, Ciarametaro M, Hahn B, et al. Cost efficiency of anticoagulation with warfarin to prevent stroke in medicare beneficiaries with nonvalvular atrial fibrillation. Stroke. 2011;42(1):112–8.CrossRef
8.
go back to reference Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.CrossRef Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.CrossRef
9.
go back to reference Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676–82.CrossRef Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676–82.CrossRef
10.
go back to reference Haque, Harisul. 2014 Guideline for the Management of Patients with Atrial Fibrillation (AFib). Univ Heart J. 2014;9(1):1-2. Haque, Harisul. 2014 Guideline for the Management of Patients with Atrial Fibrillation (AFib). Univ Heart J. 2014;9(1):1-2.
11.
go back to reference January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):2071–104.CrossRef January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):2071–104.CrossRef
12.
go back to reference January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2019;74(1):104–32.CrossRef January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2019;74(1):104–32.CrossRef
13.
go back to reference Association EHR, Camm AJ, Kirchhof P, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31(19):2369–429.CrossRef Association EHR, Camm AJ, Kirchhof P, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31(19):2369–429.CrossRef
14.
go back to reference Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016;18(11):1609–78.CrossRef Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016;18(11):1609–78.CrossRef
15.
go back to reference Kotalczyk A, Lip GY, Calkins H. The 2020 ESC Guidelines on the Diagnosis and Management of Atrial Fibrillation. Arrhythm Electrophysiol Rev. 2021;10(2):65–7.CrossRef Kotalczyk A, Lip GY, Calkins H. The 2020 ESC Guidelines on the Diagnosis and Management of Atrial Fibrillation. Arrhythm Electrophysiol Rev. 2021;10(2):65–7.CrossRef
16.
go back to reference King A. Atrial fibrillation: HAS-BLED–a new risk score to predict bleeding in patients with AF. Nat Rev Cardiol. 2011;8(2):64.CrossRef King A. Atrial fibrillation: HAS-BLED–a new risk score to predict bleeding in patients with AF. Nat Rev Cardiol. 2011;8(2):64.CrossRef
17.
go back to reference Mori N, Sotomi Y, Hirata A, Hirayama A, Sakata Y, Higuchi Y. External Validation of the ORBIT Bleeding Score and the HAS-BLED Score in Nonvalvular Atrial Fibrillation Patients Using Direct Oral Anticoagulants (Asian Data from the DIRECT Registry). Am J Cardiol. 2019;124(7):1044–8.CrossRef Mori N, Sotomi Y, Hirata A, Hirayama A, Sakata Y, Higuchi Y. External Validation of the ORBIT Bleeding Score and the HAS-BLED Score in Nonvalvular Atrial Fibrillation Patients Using Direct Oral Anticoagulants (Asian Data from the DIRECT Registry). Am J Cardiol. 2019;124(7):1044–8.CrossRef
18.
go back to reference Maes F, Dalleur O, Henrard S, et al. Risk scores and geriatric profile: can they really help us in anticoagulation decision making among older patients suffering from atrial fibrillation? Clin Interv Aging. 2014;9:1091–9.PubMedPubMedCentral Maes F, Dalleur O, Henrard S, et al. Risk scores and geriatric profile: can they really help us in anticoagulation decision making among older patients suffering from atrial fibrillation? Clin Interv Aging. 2014;9:1091–9.PubMedPubMedCentral
19.
go back to reference Hagerty T, Rich MW. Fall risk and anticoagulation for atrial fibrillation in the elderly: A delicate balance. Cleveland Clin J Med. 2017;84(1):35–40. Hagerty T, Rich MW. Fall risk and anticoagulation for atrial fibrillation in the elderly: A delicate balance. Cleveland Clin J Med. 2017;84(1):35–40.
20.
go back to reference Kirchhof P, Ammentorp B, Darius H, et al. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events–European Registry in Atrial Fibrillation (PREFER in AF). Europace. 2014;16(1):6–14.CrossRef Kirchhof P, Ammentorp B, Darius H, et al. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events–European Registry in Atrial Fibrillation (PREFER in AF). Europace. 2014;16(1):6–14.CrossRef
21.
go back to reference Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006;151(3):713–9.CrossRef Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006;151(3):713–9.CrossRef
22.
go back to reference Bahri O, Roca F, Lechani T, et al. Underuse of oral anticoagulation for individuals with atrial fibrillation in a nursing home setting in France: comparisons of resident characteristics and physician attitude. J Am Geriatr Soc. 2015;63(1):71–6.CrossRef Bahri O, Roca F, Lechani T, et al. Underuse of oral anticoagulation for individuals with atrial fibrillation in a nursing home setting in France: comparisons of resident characteristics and physician attitude. J Am Geriatr Soc. 2015;63(1):71–6.CrossRef
23.
go back to reference Barnes GD, Gu X, Haymart B, et al. The predictive ability of the CHADS2 and CHA2DS2-VASc scores for bleeding risk in atrial fibrillation: the MAQI(2) experience. Thromb Res. 2014;134(2):294–9.CrossRef Barnes GD, Gu X, Haymart B, et al. The predictive ability of the CHADS2 and CHA2DS2-VASc scores for bleeding risk in atrial fibrillation: the MAQI(2) experience. Thromb Res. 2014;134(2):294–9.CrossRef
24.
go back to reference Chao TF, Liu CJ, Lin YJ, et al. Oral Anticoagulation in Very Elderly Patients with Atrial Fibrillation - A Nationwide Cohort Study. Circulation. 2018;138(1):37-47. Chao TF, Liu CJ, Lin YJ, et al. Oral Anticoagulation in Very Elderly Patients with Atrial Fibrillation - A Nationwide Cohort Study. Circulation. 2018;138(1):37-47.
25.
go back to reference Mazurek M, Huisman MV, Lip GYH. Registries in Atrial Fibrillation: From Trials to Real-Life Clinical Practice. Am J Med. 2016;130(2):135–45.CrossRef Mazurek M, Huisman MV, Lip GYH. Registries in Atrial Fibrillation: From Trials to Real-Life Clinical Practice. Am J Med. 2016;130(2):135–45.CrossRef
26.
go back to reference Hart Robert G, Pearce Lesly A, Aguilar Maria I. Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation. Ann Intern Med. 2007;146(12):857–67. Hart Robert G, Pearce Lesly A, Aguilar Maria I. Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation. Ann Intern Med. 2007;146(12):857–67.
27.
go back to reference Bauersachs RM, Herold J. Oral Anticoagulation in the Elderly and Frail. Hamostaseologie. 2020;40(1):74–83.CrossRef Bauersachs RM, Herold J. Oral Anticoagulation in the Elderly and Frail. Hamostaseologie. 2020;40(1):74–83.CrossRef
28.
go back to reference Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–62.CrossRef Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–62.CrossRef
29.
go back to reference Andreas W, Eduard S, Lip GYH, Lane DA. Impact of advanced age on management and prognosis in atrial fibrillation: insights from a population-based study in general practice. Age Ageing. 2015;44(5):874–8.CrossRef Andreas W, Eduard S, Lip GYH, Lane DA. Impact of advanced age on management and prognosis in atrial fibrillation: insights from a population-based study in general practice. Age Ageing. 2015;44(5):874–8.CrossRef
30.
go back to reference Donzé J, Clair C, Hug B, et al. Risk of Falls and Major Bleeds in Patients on Oral Anticoagulation Therapy. Am J Med. 2012;125(8):773–8.CrossRef Donzé J, Clair C, Hug B, et al. Risk of Falls and Major Bleeds in Patients on Oral Anticoagulation Therapy. Am J Med. 2012;125(8):773–8.CrossRef
Metadata
Title
Barriers to prescribing oral anticoagulants to inpatients aged 80 years and older with nonvalvular atrial fibrillation: a cross-sectional study
Authors
Xin Xia
Lishuang Wang
Taiping Lin
Jirong Yue
Zhonghua Yang
Chongqing Mi
Zaibo Liao
Yanyu Chen
Ning Ge
Chenkai Wu
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Geriatrics / Issue 1/2022
Electronic ISSN: 1471-2318
DOI
https://doi.org/10.1186/s12877-022-02965-0

Other articles of this Issue 1/2022

BMC Geriatrics 1/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine